On August 25, REMEGEN rose 5.12% in regular trading, trading at HK$77.9/share, with turnover of HK$108 million.

On the news front, the company disclosed its half-year report on the evening of August 24, revealing H1 revenue of RMB 5.853 billion, up 433.11% year-over-year; net profit attributable to shareholders of RMB 4.662 billion, swinging from a loss of RMB 450 million in the same period last year; and operating cash flow of RMB 4.214 billion, surging 1,816.2% year-over-year. The strong earnings turnaround was primarily driven by continued domestic sales growth of core products Telitacicept and Disitamab Vedotin, along with significant technology licensing revenue recognized from the exclusive licensing agreement signed with AbbVie for RC148 covering ex-China rights. The broader biotech sector traded positively, with Everest Medicines up 4.31% and BeiGene up 1.54%, providing additional sector tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)